ASSAY DEVICE MEASURING VISCOSITY AND DETECTING OR MEASURING A BIOMAKER

Abstract

An assay device for use with samples of biological fluid, the assay device comprising: a physical detection unit for measuring a viscosity of a biological fluid sample; and a biomarker detection unit for detecting and/or measuring a biomarker in the biological fluid sample, wherein the physical detection unit and the biomarker detection unit act together as part of an assay process.

Claims

1. An assay device for use with samples of biological fluid, the assay device comprising: a physical detection unit for measuring a viscosity of a biological fluid sample; and a biomarker detection unit for detecting and/or measuring a biomarker in the biological fluid sample, wherein the physical detection unit and the biomarker detection unit act together as part of an assay process.

2. An assay device according to claim 1, wherein the physical detection unit comprises a channel and a plurality of detectors spaced along the channel to detect movement of the biological fluid sample along the channel.

3. An assay device according to claim 2, wherein the physical detection unit measures the rate of movement of the biological fluid sample along the channel.

4. An assay device according to claim 2, wherein the channel is a capillary channel.

5. An assay device according to claim 2, wherein the detectors are optical detectors.

6. An assay device according to claim 1, wherein the biomarker detection unit is for detecting and/or measuring at least one biomarker selected from Procalcitonin, C-reactive protein (CRP), cytokines, alpha-fetoprotein, beta-2-microglobulin, calcitonin, immunoglobulins, D-dimer and troponin in the biological fluid sample.

7. An assay device according to claim 1, wherein the biomarker detection unit comprises at least one vessel in which a biological assay is conducted.

8. An assay device according to claim 1, wherein the physical detection unit and the biomarker detection unit are housed in a removable and/or disposable detection cartridge.

9. An assay device according to claim 8, wherein the detection cartridge comprises a lab on a chip unit.

10. An assay device according to claim 1, further comprising a removable and/or disposable sample cartridge.

11. An assay device according to claim 1, further comprising a filter located at or near to a fluid introducing portion.

12. An assay device according to claim 1, further comprising a molecular amplification unit located at or near to a fluid introducing portion.

13. An assay device according to claim 1, further comprising: a processing unit arranged to operate on the viscosity and biomarker measurements to determine an output; and an output unit arranged to provide the output to a user.

14. An assay device according to claim 13, further comprising a memory unit to store the viscosity and biomarker measurements.

15. An assay device according to claim 13, wherein the processing unit is arranged to operate to determine an output which is a diagnosis of a disease and/or which is indicative of a disease state for a patient, wherein the disease is selected from one or more of an infectious disease, arthritis, cancer and stroke.

16. An assay device according to claim 15, wherein the disease is sepsis.

17. A method of generating an output, which is a diagnosis of a disease and/or which is indicative of a disease state for a patient, the method comprising: receiving a biological fluid sample from a patient at an assay device, wherein the assay device comprises a physical detection unit and a biomarker detection unit; together measuring a viscosity of the biological fluid sample and detecting and/or measuring a biomarker in the biological fluid sample to provide viscosity and biomarker measurements; and operating on the viscosity and biomarker measurements together to determine the output for the patient.

18. A method according to claim 17, further comprising storing the viscosity and biomarker measurements in a memory unit.

19. A method according to claim 17, wherein the assay device comprises: a physical detection unit for measuring a viscosity of a biological fluid sample; and a biomarker detection unit for detecting and/or measuring a biomarker in the biological fluid sample, wherein the physical detection unit and the biomarker detection unit act together as part of an assay process.

20. A method according to claim 17, wherein: the biomarker is selected from the amount and/or presence of at least one biomarker selected from Procalcitonin, C-reactive protein (CRP), cytokines, alpha-fetoprotein, beta-2-microglobulin, calcitonin, immunoglobulins, D-dimer and troponin in the biological fluid sample; and disease is selected from one or more of an infectious disease, arthritis, cancer and stroke.

21. (canceled)

22. A method according to claim 20, wherein the disease is sepsis.

23. A method of identifying a patient having a disease that is responsive to a particular treatment for said disease, the method comprising: determining a disease state for the patient; providing a treatment appropriate to the disease; monitoring the disease state by: receiving a biological fluid sample from the patient at an assay device, wherein the assay device comprises a physical detection unit and a biomarker detection unit; together measuring a viscosity of the biological fluid sample and detecting and/or measuring a biomarker in the biological fluid sample to provide viscosity and biomarker measurements; and operating on the viscosity and biomarker measurements together to determine the output for the patient; and identifying the patient as responsive to the particular treatment according to changes in the monitored disease state.

24. A method of assaying the efficacy of a particular treatment for a disease in a patient, said method comprising: identifying a patient having a disease; determining a disease state for the patient; providing a treatment appropriate to the disease; monitoring the disease state by: receiving a biological fluid sample from the patient at an assay device, wherein the assay device comprises a physical detection unit and a biomarker detection unit; together measuring a viscosity of the biological fluid sample and detecting and/or measuring a biomarker in the biological fluid sample to provide viscosity and biomarker measurements; and operating on the viscosity and biomarker measurements together to determine the output for the patient; and identifying the particular treatment as effective according to changes in the monitored disease state.

25. (canceled)

Description

BRIEF DESCRIPTION OF DRAWINGS

[0085] For a better understanding of the invention, and to show how exemplary embodiments of the same may be carried into effect, reference will be made, by way of example only, to the accompanying diagrammatic Figures, in which:

[0086] FIG. 1 shows a schematic view of an assay device according to the first aspect of the invention;

[0087] FIG. 2 shows a schematic view of a suitable arrangement of a physical detection unit and a biomarker detection unit in an assay device according to the first aspect of the invention;

[0088] FIG. 3 shows a schematic view of an alternative suitable arrangement of a physical detection unit and a biomarker detection unit in an assay device according to the first aspect of the invention;

[0089] FIG. 4 shows a schematic view of a suitable arrangement of an assay device according to the first aspect of the invention including the physical detection unit of FIG. 3;

[0090] FIG. 5 shows a schematic view of the assay device shown in FIG. 4 after the cartridge has been inserted;

[0091] FIG. 6 shows an internal schematic view of the assay device shown in FIG. 4; and

[0092] FIG. 7 shows an example flow diagram illustrating steps of a method of generating an output which is a diagnosis of a disease according to the second aspect of the invention.

DESCRIPTION OF EMBODIMENTS

[0093] FIG. 1 shows a schematic view of an assay device 1 for use with samples of biological fluid, according to a first example embodiment of the invention. The assay device 1 of FIG. 1 comprises a detection cartridge 10, a memory unit 20, a processing unit 30 and an output unit 40. The detection cartridge 10 comprises a physical detection unit 50 and a biomarker detection unit 60.

[0094] The physical detection unit 50 and the biomarker detection unit 60 are arranged to receive the same biological fluid sample from a patient, which in this example embodiment is blood plasma. The physical detection unit 50 is arranged to measure a viscosity of the biological fluid sample. The biomarker detection unit 60 is arranged to detect and/or measure a biomarker in the biological fluid sample. In this example embodiment the biomarker detection unit 60 is arranged to detect and measure Procalcitonin levels in the biological fluid sample. However, additional and/or alternative biomarkers may be detected and/or measured in the biological fluid sample.

[0095] The memory unit 20 is arranged to store viscosity and biomarker measurements. The memory unit 20 comprises a number of storage areas. In a first storage area 21 a database including current, and optionally historical, viscosity and biomarker measurements is stored. The database further includes timestamps indicating the time at which viscosity and biomarker measurements were generated and received. The first storage area 21 may also store viscosity and biomarker values calculated by the processing unit as discussed below. In a second storage area 22 the memory unit 20 stores data used to control and inform operation of the processing unit 30, as described below.

[0096] The processing unit 30 is arranged to operate on the measurements stored in the memory unit 20 to generate an output. For example, the processing unit 30 calculates a value for the dynamic viscosity of the biological fluid sample from the rate of movement of the sample. The processing unit 30 also calculates a value for the Procalcitonin level for the biological fluid sample from the measured biomarker. Biomarkers for Procalcitonin are well known to persons skilled in the art. The processing unit 30 may also operate on the viscosity and biomarker values in the memory unit 20 to determine a diagnosis and/or an indication of a disease state for the patient.

[0097] The processing unit 30 loads the viscosity and biomarker measurements from the first memory area 21 of the memory unit 20 and operates thereon according to control data loaded from the second memory area 22 of the memory 30. As a result of the operations of the processing unit 30 values of viscosity and/or biomarker values, and/or a diagnosis and/or an indication of a disease state, are determined and passed to the output unit 40. Any of the viscosity values, biomarker values, determined diagnosis and/or indication of a disease state may be stored in the memory unit 20, particularly in the first memory area 21, to be available for later use, for example to be used at a future time so as to monitor the disease state of a particular patient.

[0098] The output unit 40 comprises a communication capability for transferring data from the device to a user. For example, the output unit 40 provides a local user with immediate feedback via a display, according to any of the determined viscosity values, biomarker values, diagnosis and/or disease state. The data may be transmitted to a remote user for review and/or storage if required.

[0099] Whilst FIG. 1 shows the detection unit adjacent to the processing, memory and output units, these units may of course be arranged in any suitable alternative arrangement.

[0100] FIG. 2 shows a schematic view of a suitable detection cartridge 10 comprising a physical detection unit 50 and a biomarker detection unit 60 for use in an assay device 1 according to the first aspect of the invention.

[0101] The physical detection unit 50 and the biomarker detection unit 60 are arranged to receive the same biological fluid sample from a patient, which in this example embodiment is whole blood. The whole blood is input into a sample application area 11 and passes through a plasma filter 12 into a receiving vessel 13.

[0102] From the receiving vessel 13, a portion of the blood plasma passes to the physical detection unit 50. The physical detection unit 50 is arranged to measure a viscosity of the blood plasma sample. The physical detection unit 50 comprises a capillary channel 14, which is curved so as to fit into a small space. However, it should be appreciated that any arrangement of the capillary channel 14 may be suitable. The physical detection unit 50 also comprises a plurality of optical detectors 15 spaced along the capillary channel 14. The optical detectors 15 detect movement of the blood plasma sample as it passes along the capillary channel 14. The device comprises a timer (not shown) which measures a series of time points as the blood plasma sample is detected by each of the optical detectors 15 passing through the capillary channel 14, so as to measure the time taken for the blood plasma sample to move along the capillary channel 14.

[0103] From the receiving vessel 13, another portion of the blood plasma passes to the biomarker detection unit 60. The biomarker detection unit 60 is arranged to detect and/or measure a biomarker in the biological fluid sample. In this example embodiment the biomarker detection unit 60 is arranged to detect and measure Procalcitonin levels in the biological fluid sample. However, additional and/or alternative biomarkers may be detected and measured in the biological fluid sample.

[0104] The biomarker detection unit 60 comprises a first cartridge 61 and a second cartridge 62. The first cartridge 61 acts as a baseline. In the second cartridge 62 Procalcitonin is detected and measured in the sample. The amount of Procalcitonin is determined by measuring a change in optical absorbance at a specified wavelength between the first and second cartridges. The biomarker detection unit 60 may alternatively or additionally be used to conduct infectious disease testing on the biological fluid sample, for example to conduct the TORCH test. Whilst FIG. 2 shows a single cartridge in which the biomarker assay is conducted, it is possible for the assay device to include additional cartridges in which further biomarker assays are conducted, as required for a particular disease.

[0105] FIG. 2 shows that the receiving vessel 13 includes two separate outputs, a first output 16 which leads to the capillary channel 14 of the physical detection unit 50 and a second output 17 which leads to the biomarker detection unit 60. In the example embodiment shown in FIG. 2, the first output 16 is located above the second output 17 so that in use the blood plasma sample that reaches the first output 16 passes to the capillary channel 14 of the physical detection unit and when the blood plasma sample drops below the first output 16 it reaches the lower second output 17 and passes to the biomarker detection unit 60. The blood plasma sample passes from the second output 17 to the biomarker detection unit 60 by means of a capillary channel, i.e. under capillary action. As the skilled person would appreciate, alternative ways of portioning the blood plasma sample to the physical detection unit 50 and biomarker detection unit 60 could be used.

[0106] FIG. 3 shows a schematic view of an alternative suitable detection cartridge 100 comprising a physical detection unit 150 and a biomarker detection unit 160 for use in an assay device 1 according to the first aspect of the invention.

[0107] The physical detection unit 150 and the biomarker detection unit 160 are arranged to receive the same biological fluid sample from a patient, which in this example embodiment is whole blood. The whole blood is input into a sample cartridge 110 and passes through a plasma filter 111 into a channel 112.

[0108] From the channel 112, a portion of the blood plasma passes to the physical detection unit 150. The physical detection unit 150 is arranged to measure a viscosity of the blood plasma sample. The physical detection unit 150 comprises a baseline vessel 113, an endpoint vessel 114 and a capillary channel 115 extending from the baseline vessel 113 to the endpoint vessel 114. The capillary channel 115 is shaped so as to fit into a small space. However, it should be appreciated that any arrangement of the capillary channel 115 may be suitable. The physical detection unit 150 also comprises an optical detector 116 located at the baseline vessel 113 and an optical detector 117 located at the endpoint vessel 114. The optical detectors 116, 117 detect movement of the blood plasma sample as it passes from the baseline vessel 113 along the capillary channel 115 to the endpoint vessel 114. The device comprises a timer (not shown) which starts when the blood plasma sample is detected passing through the baseline vessel 113 and stops when the blood plasma sample is detected passing through the endpoint vessel 114, so as to measure the time taken for the blood plasma sample to move between these two points.

[0109] From the sample cartridge 110, another portion of the blood plasma passes to the biomarker detection unit 160. The blood plasma sample passes from the sample cartridge 110 to the biomarker detection unit 160 by means of a capillary channel, i.e. under capillary action. The biomarker detection unit 160 is arranged to detect and/or measure a biomarker in the biological fluid sample. In this example embodiment the biomarker detection unit 160 is arranged to detect and measure Procalcitonin levels in the biological fluid sample. However, additional and/or alternative biomarkers may be detected and measured in the biological fluid sample.

[0110] The biomarker detection unit 160 comprises a first area 161 and a second area 162 in which Procalcitonin is detected and measured in the sample. The amount of Procalcitonin is determined by measuring a change in optical absorbance at a specified wavelength between the first and second areas. The biomarker detection unit 160 may alternatively or additionally be used to conduct infectious disease testing on the biological fluid sample, for example to conduct the TORCH test.

[0111] FIG. 4 shows a schematic view of a suitable arrangement of an assay device 1 according to the first aspect of the invention which comprises a housing 90 in which a cartridge slot 70 is located. The disposable detection cartridge 10 can be input into the assay device via the cartridge slot 70. The detection cartridge 10 can be removed from the assay device 1 after use. FIG. 4 shows a detection cartridge 10 as shown in FIG. 3 but any suitable detection cartridge according to the invention may be used. The assay device 1 shown in FIG. 4 comprises an output unit 40 in the form of a display and a user input unit 80. The user input unit 80 is used to input information, for example about the patient. The memory unit 20 and the processing unit 30are not shown in FIG. 4 but are housed internally beneath the output unit 40 and user input unit 80.

[0112] FIG. 5 shows the assay device 1 of FIG. 4 in which the detection cartridge 10 has been inserted, i.e. by means of the cartridge slot 70. The sample cartridge 110 extends from the housing of the assay device 1 to enable easy input of the biological fluid sample. Other arrangements for the input of the biological fluid sample may be used however.

[0113] FIG. 6 shows an internal schematic view of the assay device shown in FIG. 4. In the arrangement shown in FIG. 6, when input into the assay device 1, the detection cartridge 10 is located substantially internally of the housing 90 and beneath the output unit 40 and the user input unit 80. The memory unit 20 and the processing unit 30 are not shown in FIG. 6 but are housed internally beneath the output unit 40 and user input unit 80. The optical detectors 116, 117 each comprise an optical emitter 118, 119 and an optical detector 120, 121. In this example embodiment the biomarker detection unit 160 is arranged to detect and measure Procalcitonin levels in the biological fluid sample by means of colorimetric measurements. The colorimetric measurements are made by means of optical emitters 122, 123 and optical detectors 124, 125.

[0114] FIG. 7 shows an example flow diagram illustrating steps of a method of generating an output which is a diagnosis of sepsis.

[0115] In the first step, the measured dynamic viscosity value is compared to the values for a healthy adult and determined either as below the normal value, normal or above the normal value. If the measured dynamic viscosity value is above the normal value then, in the next step, the measured Procalcitonin level is the compared to the values for a healthy adult.

[0116] As shown in FIG. 7, when the measured value of Procalcitonin concentration is higher than about 0.5 ng/ml, then the output is that the patient may have an infectious disease but sepsis is unlikely. When the measured value of Procalcitonin concentration is higher than about 0.5 ng/ml and lower than about 2 ng/ml then the output is that the patient may have a systemic infection and sepsis is possible. When the measured value of Procalcitonin concentration is higher than about 2 ng/ml and lower than about 10 ng/ml then the output is that the patient is likely to have a systemic infection and sepsis is likely. When the measured value of Procalcitonin concentration is higher than about 10 ng/ml then the output is that the patient has a major systemic inflammatory response indicative of sepsis.

[0117] Attention is directed to all papers and documents which are filed concurrently with or previous to this specification in connection with this application and which are open to public inspection with this specification, and the contents of all such papers and documents are incorporated herein by reference.

[0118] All of the features disclosed in this specification (including any accompanying claims, and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive.

[0119] Each feature disclosed in this specification (including any accompanying claims, abstract and drawings) may be replaced by alternative features serving the same, equivalent or similar purpose, unless expressly stated otherwise. Thus, unless expressly stated otherwise, each feature disclosed is one example only of a generic series of equivalent or similar features.

[0120] The invention is not restricted to the details of the foregoing embodiment(s). The invention extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.